16.4 C
New York
Tuesday, June 9, 2026

Tag: assessments

newssourceFORcompanyinformationcontent1marketreleases

XRP Healthcare Reports More Than 74,000 Ecosystem Users as AI Healthcare Platform Delivers $1.2 Million in Prescription Savings

DUBAI, UAE, June 9, 2026 /PRNewswire/ -- XRP Healthcare, the first AI healthcare platform built on the XRP Ledger, today announced continued growth across...

EHang Reports First Quarter 2026 Unaudited Financial Results

GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.

KinoSec Launches a Cross-Domain Autonomous Penetration Testing Platform

KinoSec's autonomous penetration testing platform continuously identifies and exploits vulnerabilities before attackers are able to.SAN FRANCISCO, June 8, 2026 /PRNewswire/ -- KinoSec has launched...

KinoSec Launches a Cross-Domain Autonomous Penetration Testing Platform

KinoSec's autonomous penetration testing platform continuously identifies and exploits vulnerabilities before attackers are able to.SAN FRANCISCO, June 8, 2026 /PRNewswire/ -- KinoSec has launched...

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

Lucid Rolls Out Hands-Free Driving Assist and New Software Features for Lucid Gravity in North America

NEWARK, Calif., June 8, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

In HelloNation, Auto Industry Experts David Mantz and David Mantz Jr. Examine Choosing the Right Mechanic in Southington, Connecticut

The article explains how to evaluate transparency, consistency, and preventative maintenance when selecting an auto repair company.SOUTHINGTON, Conn., June 5, 2026 /PRNewswire/ -- What...

Orla Mining Reports Resumption of Operations at Camino Rojo

VANCOUVER, BC, June 5, 2026 /CNW/ - Orla Mining Ltd. (TSX: OLA; NYSE: ORLA) ("Orla" or the "Company") is pleased to report that the...

Altimetrik Named Product Challenger in ISG Provider Lens™ 2026 for Global Capability Center Services

BENGALURU, India, June 5, 2026 /PRNewswire/ -- Altimetrik, an AI-first digital engineering company, has been named a Product Challenger in the Design and Setup...

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAssessments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers